FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955146074> ?p ?o ?g. }

• W2955146074 abstract "Genetically-unstable cancer cells have supernumerary centrosomes and aneuploidy (a hallmark of cancer). CDK2 antagonism inhibits clustering of excessive centrosomes at mitosis leading to multipolar cell division and apoptotic death. This process is called anaphase catastrophe. Anaphase catastrophe affects preferentially aneuploid cancer cells while sparing normal cells with two centrosomes. CYC065 (Cyclacel) is a next-generation CDK2/9 inhibitor that is undergoing clinical trials. Here, we explored CYC065 activity against aneuploid lung and other cancers. CYC065 substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in murine (ED1, LKR13, and 393P) and human (Hop62, A549, and H1299) lung cancer cells. In marked contrast, these effects were largely unseen in bipolar immortalized pulmonary epithelial (murine C10 and human BEAS-2B) cells. Notably, anaphase catastrophe was induced by CYC065-treatment even in pancreatic and colon cancers that are often driven by the KRAS oncoprotein. This suggests that engaging anaphase catastrophe is a general antineoplastic mechanism. Comprehensive expression analysis of nearly 300 growth-regulatory proteins was performed after CYC065 treatment in lung cancer cells using Reverse Phase Protein Arrays (RPPAs). In addition to known CDK targets (such as phosphorylated retinoblastoma protein), FAK phosphorylation and SAC phosphorylation that are known to regulate metastasis were unexpectedly down-regulated. Consistent with this finding, in vitro migration and invasion CYC065 treatment assays markedly inhibited migration and invasion of lung cancer cells. CYC065 anti-neoplastic effects were interrogated in mice. CYC065 significantly inhibited tumor growth in several lung cancer syngeneic xenografts and patient-derived xenografts (PDXs) and reduced metastasis of 344SQ lung cancer cells in a syngeneic tail-vein injection model. Immunohistochemistry (IHC) studies of resected PDX tumors revealed downregulation of p-CDK2 (Thr160) and MCL1 expression after CYC065 treatment which is consistent with CDK2/9 antagonism, respectively. In summary, CYC065 engages anaphase catastrophe and elicits marked antineoplastic effects in diverse cancers. These effects are due to mechanisms that confer after CDK2/9 inhibition, anaphase catastrophe, MCL1 down-regulation and suppression of proteins that regulate metastasis. Taken together, findings reveal that anaphase catastrophe is a general antineoplastic mechanism engaged in aneuploid cancers. Intriguingly, this mechanism is activated after CDK2/9 inhibition of lung and other cancers, including those driven by the KRAS oncoprotein. Citation Format: Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen, Zibo Chen, Jason Roszik, Xi Liu, Ethan Dmitrovsky. Next generation CDK2/9 inhibitor CYC065 triggers anaphase catastrophe in diverse aneuploid cancers and markedly inhibits growth and metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4407." @default.
• W2955146074 created "2019-07-12" @default.
• W2955146074 creator A5021388330 @default.
• W2955146074 creator A5048093668 @default.
• W2955146074 creator A5067021586 @default.
• W2955146074 creator A5083247969 @default.
• W2955146074 creator A5086058658 @default.
• W2955146074 creator A5087353780 @default.
• W2955146074 creator A5091028729 @default.
• W2955146074 date "2019-07-01" @default.
• W2955146074 modified "2023-09-28" @default.
• W2955146074 title "Abstract 4407: Next generation CDK2/9 inhibitor CYC065 triggers anaphase catastrophe in diverse aneuploid cancers and markedly inhibits growth and metastasis" @default.
• W2955146074 doi "https://doi.org/10.1158/1538-7445.sabcs18-4407" @default.
• W2955146074 hasPublicationYear "2019" @default.
• W2955146074 type Work @default.
• W2955146074 sameAs 2955146074 @default.
• W2955146074 citedByCount "0" @default.
• W2955146074 crossrefType "proceedings-article" @default.
• W2955146074 hasAuthorship W2955146074A5021388330 @default.
• W2955146074 hasAuthorship W2955146074A5048093668 @default.
• W2955146074 hasAuthorship W2955146074A5067021586 @default.
• W2955146074 hasAuthorship W2955146074A5083247969 @default.
• W2955146074 hasAuthorship W2955146074A5086058658 @default.
• W2955146074 hasAuthorship W2955146074A5087353780 @default.
• W2955146074 hasAuthorship W2955146074A5091028729 @default.
• W2955146074 hasConcept C10447061 @default.
• W2955146074 hasConcept C121608353 @default.
• W2955146074 hasConcept C142724271 @default.
• W2955146074 hasConcept C186000732 @default.
• W2955146074 hasConcept C2776256026 @default.
• W2955146074 hasConcept C2779013556 @default.
• W2955146074 hasConcept C2781187634 @default.
• W2955146074 hasConcept C29537977 @default.
• W2955146074 hasConcept C502942594 @default.
• W2955146074 hasConcept C526805850 @default.
• W2955146074 hasConcept C53420372 @default.
• W2955146074 hasConcept C54355233 @default.
• W2955146074 hasConcept C71924100 @default.
• W2955146074 hasConcept C86803240 @default.
• W2955146074 hasConcept C93304396 @default.
• W2955146074 hasConcept C95444343 @default.
• W2955146074 hasConcept C96232424 @default.
• W2955146074 hasConceptScore W2955146074C10447061 @default.
• W2955146074 hasConceptScore W2955146074C121608353 @default.
• W2955146074 hasConceptScore W2955146074C142724271 @default.
• W2955146074 hasConceptScore W2955146074C186000732 @default.
• W2955146074 hasConceptScore W2955146074C2776256026 @default.
• W2955146074 hasConceptScore W2955146074C2779013556 @default.
• W2955146074 hasConceptScore W2955146074C2781187634 @default.
• W2955146074 hasConceptScore W2955146074C29537977 @default.
• W2955146074 hasConceptScore W2955146074C502942594 @default.
• W2955146074 hasConceptScore W2955146074C526805850 @default.
• W2955146074 hasConceptScore W2955146074C53420372 @default.
• W2955146074 hasConceptScore W2955146074C54355233 @default.
• W2955146074 hasConceptScore W2955146074C71924100 @default.
• W2955146074 hasConceptScore W2955146074C86803240 @default.
• W2955146074 hasConceptScore W2955146074C93304396 @default.
• W2955146074 hasConceptScore W2955146074C95444343 @default.
• W2955146074 hasConceptScore W2955146074C96232424 @default.
• W2955146074 hasLocation W29551460741 @default.
• W2955146074 hasOpenAccess W2955146074 @default.
• W2955146074 hasPrimaryLocation W29551460741 @default.
• W2955146074 hasRelatedWork W1967019500 @default.
• W2955146074 hasRelatedWork W1969256437 @default.
• W2955146074 hasRelatedWork W2007681326 @default.
• W2955146074 hasRelatedWork W2014476817 @default.
• W2955146074 hasRelatedWork W2041292405 @default.
• W2955146074 hasRelatedWork W2056528509 @default.
• W2955146074 hasRelatedWork W2083174040 @default.
• W2955146074 hasRelatedWork W2143052991 @default.
• W2955146074 hasRelatedWork W2150778145 @default.
• W2955146074 hasRelatedWork W2159776731 @default.
• W2955146074 hasRelatedWork W2528498371 @default.
• W2955146074 hasRelatedWork W2562445606 @default.
• W2955146074 hasRelatedWork W2740162751 @default.
• W2955146074 hasRelatedWork W2794019434 @default.
• W2955146074 hasRelatedWork W2886911223 @default.
• W2955146074 hasRelatedWork W2915929729 @default.
• W2955146074 hasRelatedWork W2979518321 @default.
• W2955146074 hasRelatedWork W3047188842 @default.
• W2955146074 hasRelatedWork W3108650465 @default.
• W2955146074 hasRelatedWork W3198136406 @default.
• W2955146074 isParatext "false" @default.
• W2955146074 isRetracted "false" @default.
• W2955146074 magId "2955146074" @default.
• W2955146074 workType "article" @default.